The Authors' Reply
Year of publication: |
2012
|
---|---|
Authors: | Bounthavong, Mark ; Nguyen, Christine M. ; Mendes, Margaret A.S. ; Christopher, Melissa L.D. ; Tran, Josephine N. ; Kazerooni, Rashid ; Morreale, Anthony P. |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 30.2012, 10, p. 977-978
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Adalimumab | Certolizumab-pegol | Cost-utility | Disease-modifying-antirheumatics | Etanercept | Golimumab | Infliximab | Methotrexate | Rheumatoid-arthritis | Tumour-necrosis-factor-alpha-inhibitors |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
Nguyen, Christine M., (2012)
-
(2012)
-
Validity of Cost and Utility Results?
Diamantopoulos, Alex, (2012)
- More ...
-
Nguyen, Christine M., (2012)
-
Bounthavong, Mark, (2012)
-
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis
Nguyen, Christine, (2012)
- More ...